Skip to main content

New at Switzerland Innovation Park Basel Area: SunRegen

| News

New at Switzerland Innovation Park Basel Area: SunRegen

05.03.2019

The biopharmaceutical company SunRegen Healthcare develops a therapy for neurodegenerative eye diseases like Optic Atrophy. The two co-founders and managers Dr. Yuhong Dong and Mr. David Guan moved their young startup to the Switzerland Innovation Park Basel Area in Allschwil in January 2019.

Yuhong Dong and David Guan, SunRegen Healthcare

In 2020 they hope to reach the next milestone and move their project from preclinical to clinical stage for their lead compound SBC003. This synthetic molecule is derived from a natural active ingredient that can be found in a medical herb used in the oriental medicine. Yuhong and David plan to test their compound for ALS as another target indication. Further, they want to test SBC003 for other neurological and neuromuscular diseases such as Alzheimer’s, Parkinson’s or Huntington’s disease.

At the Switzerland Innovation Park Basel Area in Allschwil, the co-founders concentrate on developing their business. They are especially happy that they were able to move in and start working right from the beginning, thanks to the furnished office. To host visitors, they appreciate the coffee area that is open to all residents as well as the meeting rooms the Switzerland Innovation Park Basel Area offers. “Even before we could afford an office, the team at the Switzerland Innovation Park was very forthcoming. They are always very friendly – we really enjoy being here.”

SunRegen Healthcare is one of the participants of the first round of the BaseLaunch accelerator. Back in 2017, Yuhong and David reached Phase I of the program, benefitting from customized coaching and funding for three months. Although they were not selected for phase II, they persisted in building their startup. In 2018, they won the BIO-Europe 2018 Startup Slam Competition, held in Copenhagen and gained access to a top-tier mentoring program with industry experts from Johnson & Johnson.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Building the future of healthtech, digital health and techbio in the Basel Area

Meet our Chief Representative USA: with over 30 years in the biotech industry, Kirsten Detrick brings invaluable expertise for companies...
Read More

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Do you have a question? We'd like to hear from you.